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Renin angiotensin aldosterone (RAAS) is very well established as a regulator 
of blood pressure (BP) and a determinant of target organ injury. It controls fluid 
and electrolyte balance through coordinated effects on the heart, blood vessels, 
and kidneys. The main effector of RAAS is angiotensin II (Ang II), which exerts its 
vasoconstrictor effect primarily on the postglomerular arterioles, thereby raising 
the glomerular hydraulic pressure and ultrafiltration of plasma proteins, which 
may lead to the initiation and progression of chronic kidney disease (CKD). RAAS 
also plays a, key role in hypertension and cerebrovascular disease. Enhanced Ang 
II levels accelerate the initiation and progression of cell senescence by fostering 
inflammation and oxidative stress. Sustained activation of RAAS facilitates aging-
related CKD and results in cognitive dysfunction and Alzheimer’s disease (AD). 
However, in many hypertension treatment studies, the frequency of fatal and 
nonfatal stroke has been greatly reduced, and this is very important since a history 
of stroke doubles the risk of dementia in both patients without CKD and hemodi-
alysis. In CKD patients with AD, anemia has also been identified as a risk factor for 
cognitive impairment, and correction of anemia with recombinant erythropoietin 
treatment has been shown to enhance cognition measures, such as AD markers and 
neuropsychological tests.
Keywords: Angiotensin converting enzyme, Chronic Kidney Disease,  
Cognitive Dysfunction, Alzheimer’s disease, Amyloid β, Tau
1. Introduction
The renin angiotensin aldosterone (RAAS) system is a hormone system in the 
body that is responsible for controlling the balance of fluid and blood pressure. 
The system consists primarily of three hormones, namely renin, angiotensin II 
and aldosterone. It is controlled mainly by the rate of renal blood flow. The main 




The pathogenic mechanism of chronic kidney disease in the renin angiotensin aldosterone system.
and ultra-filtration of plasma proteins, which can contribute to the initiation and 
progression of chronic kidney disease (CKD), as well as key molecules in hyper-
tension and cerebrovascular disease, exerts its vasoconstrictor effect primarily 
on postglomerular arterioles. Enhanced Ang II levels speed up the initiation and 
progression of cell senescence by encouraging inflammation and oxidative stress. 
Sustained RAAS activation facilitates aging-related CKD and results in cognitive 
decline and Alzheimer’s disease (AD). The risk of cognitive dysfunction in CKD 
patients with AD is significantly greater than in patients without CKD [1], not only 
in aged patients with CKD, but also in young patients with CKD [2]. It has been 
believed for a long time that kidney function is associated with brain activity. Our 
recent clinical studies indicate that CKD patients are more vulnerable to cognitive 
dysfunction and AD, and the severity of cognitive dysfunction is closely linked to 
the development of CKD and kidney failure [3–5].
2. RAAS: pathogenic mechanism of chronic kidney disease
RAAS is the best known blood pressure regulator (BP) and the determinant of 
hypertension damage to the target organs. It also regulates the balance of fluids and 
electrolytes by coordinated impacts on the heart, blood vessels, and kidneys. The 
main effector of the RAAS is Ang II [6]. Renin is secreted from the juxtaglomerular 
apparatus of the kidney in the classic RAAS pathway and acts on the circulating 
precursor angiotensinogen to create angiotensin I. Angiotensin I has few effects on 
BP, and in the lungs, ACE is transformed to Ang II. Ang II operates on the heart and 
kidneys by binding to type 1 (AT1) and type 2 (AT2) G-protein coupled recep-
tors [7]. The more deleterious effects of Ang II, vasoconstriction and heart and 
vessel hypertrophy are mediated by the AT1 receptor. In addition the vasodilator 
peptide bradykininin is inactivated by the angiotensin-converting enzyme (ACE) 
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in addition to the conversion of angiotensin I to Ang II [7]. Recently, ACE type 2 
(ACE2) has been found to cleave angiotensin I into inactive angiotensin1–9, trans-
formed by ACE into vasodilator and antiproliferative angiotensin1–7, respectively 
[8, 9]. While ACE2 in the human kidney is known to be present, there was no 
evidence on the distribution of tissues in kidney disease [8]. Kidney biopsies from 
patients with different kidney disorders, including transplant patients, were studied 
in a recent review. ACE2 was present in the tubular and glomerular epithelium and 
in the vascular smooth muscle cells and the interlobular artery endothelium in the 
control kidneys [10]. Neo-expression of ACE2 has been observed in the glomerular 
and peritubular capillary endothelium in all kidney diseases. Treatment with ACE 
inhibitors did not change ACE2 expression [10]. In vivo, Ang II increases the vascu-
lar tone of both afferent and efferent glomerular arterioles and modulates capillary 
intraglomerular pressure and glomerular filtration rate (GFR). Ang II primarily 
exerts its vasoconstrictor effect on the postglomerular arterioles, thereby raising the 
glomerular hydraulic pressure and filtration fraction, and impairing the glomerular 
barrier’s selective size role for macromolecules, such as plasma proteins [11]. Intra 
capillary hypertension and increased plasma protein ultrafiltration can lead to the 
onset and progression of CKD [12]. Angiotensin non-hemodynamic effect may also 
be relevant in the progression of kidney disease [6].
A diagrammatic sketch of the pathogenic role of RAAS in chronic kidney disease 
is shown in Figure 1.
3. RAAS: pathogenic mechanism of Alzheimer’s disease
Alzheimer disease (AD) is the most common neurodegenerative disease associ-
ated with dementia in the elderly. Various mechanisms, including DNA damage, 
lysosomal dysfunction, epigenetic modulation, and immune dysregulation, have 
been involved in neurodegenerative pathogenesis. Importantly, the homeostasis 
between protein synthesis, folding, and clearance of unfolded proteins, called pro-
teostasis, is disrupted in AD and other neurodegenerative diseases. This contributes 
to an accumulation of proteins that are oligomerized and aggregated (Intracellular 
Tau (Neurofibrillary tangles [NFT]), and extracellular amyloid β (Aβ) (Senile 
plaques)) that ultimately induce protein toxicity. In many neurodegenerative disor-
ders, including AD, oxidative stress are frequently found. In AD, Aβ accumulation, 
tau hyperphosphorylation, and the resulting degradation of synapses and neurons 
may be promoted by oxidative stress. In several target cells, Ang II has been shown 
to induce mitochondrial dysfunction through angiotensin II type 1 receptor (AT1R). 
Mechanistically, Ang II increases mitochondrial reactive oxygen species (ROS) [13]. 
Several studies indicate that ROS is involved in the development of Aβ fibrillation 
and NFT in AD and increases the pathology of Aβ and NFT in AD [14, 15].
The hyperactivity of the RAAS classical axis, mediated by AT1R, is implicated in 
the pathogenesis of AD. Ang II intracerebroventricular infusion increased both of the 
amyloid-β (Aβ) [16] and tau pathology, and also reduced cognitive performance [17], 
in aged normal rats. In most but not all AD mouse models, angiotensin II type 1 recep-
tor blockers (ARBs) and angiotensin-converting enzyme inhibitors (ACEIs) minimize 
the amount of AD-like pathology and increase cognitive efficiency [18, 19]. Clinical 
studies have also identified ACE2 and ACE as brain RAAS factors, not only in the 
regulation of blood pressure, but also in the conversion of Aβ43 to Aβ40, which may 
decrease Aβ accumulation associated with AD and decrease serum ACE-2 activity in 
AD patients compared to control subjects [20].
A diagrammatic sketch of the pathogenic role of RAAS in Alzheimer’s disease is 
shown in Figure 2.
Renin-Angiotensin Aldosterone System
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4.  Hypertension is a risk factor for cognitive dysfunction in chronic 
kidney disease patients with Alzheimer’s disease
The most common neurodegenerative disorders associated with CKD in the 
elderly are AD and dementia. Ang II represents a central molecule in cerebrovascular 
pathology and hypertension. Enhanced Ang II levels speed up the initiation and 
progression of cell senescence by encouraging inflammation and oxidative stress. 
Sustained RAAS activation causes aging related end stage organ damage and results 
in cognitive decline and dementia. [21]. Studies also show that hypertension is the 
most important factor that adversely affects cerebral aging modalities and is related 
to cognitive compromise in people who are aging [22, 23]. This discovery has contrib-
uted to the belief that hypertension, up to the point of AD and dementia, is one of the 
factors responsible for the compromise of cognitive function in the elderly. It is there-
fore hypothesized that aging contributes to systemic and tissue RAAS hyperactivity 
and a rise in neurogenic hypertension, whereas evidence that connects brain RAAS 
with AD, memory, and learning develops cognitive functions [24]. In this regard, one 
of the long-term hypertension complications is clinically defined as dementia (for 
example AD) or vascular dementia, associated with diseases of the degenerative cen-
tral nervous system (CNS). The temporal association between dementia and broad 
cerebrovascular pathology indicates that there is a pattern of sudden initiation and 
progressive development of cognitive impairment in the onset of dementia within 
three months of the diagnosis of stroke. It is understood that hypertension raises the 
risks of the target organ, such as cardiomegaly, progressive hypertensive retinopathy, 
nephropathy and stroke. In addition to repeated episodes of stroke or acute ischemic 
attacks, chronic hypertension, which results in a reduction in cerebral blood flow, is 
associated with vascular dementia and results in cognitive impairment [25].
A diagrammatic sketch of the role of RAAS in the induction and mediation of 
high blood pressure and cognitive impairment in CKD patients with AD is shown in 
Figure 3.
Figure 2. 
Pathogenic Alzheimer’s disease pathway of the renin angiotensin aldosterone system.
5
The Role of Renin Angiotensin Aldosterone System in the Progression of Cognitive Dysfunction…
DOI: http://dx.doi.org/10.5772/intechopen.96048
5.  Treatment of cognitive dysfunction in chronic kidney disease patients 
with Alzheimer’s disease
Cognitive dysfunction is common among patients with CKD and dialysis in 
the memory, attention, and executive function domains. In our previous study, 
working memory and executive control, two main areas of cognitive ability, are 
potentially significant variables in drug compliance [4, 5]. Increased risk for injury, 
increased health care costs and progression to dementia are also associated with 
cognitive dysfunction without dementia [26]. Dementia is described by a drop 
in cognitive performance from a previous higher level along with a behavioral 
disorder that interferes with everyday function and independence. The brain and 
kidney vascular beds have identical anatomical and hemodynamic characteristics; 
these results have contributed to the speculation that cognitive dysfunction and 
CKD are a reflection of vascular damage in multiple end organs [26]. In addition, 
most patients with CKD have elevated rates of hypertension, diabetes, high levels 
of inflammatory receptors and vascular endothelial dysfunction, cardiovascular 
events like stroke, and carotid atherosclerosis, both leading to vascular cognitive 
decline and neurodegenerative diseases such as AD [27]. Potential steps to minimize 
cognitive impairment in CKD patients may include the treatment of cardiovascular 
risk factors, but, unfortunately, no clinical trials have been performed in CKD 
patients assessing cardiovascular risk factors for the prevention of cerebrovascular 
disease or cognitive impairment.
There is a trial showing that treatment with hypertension has a beneficial effect 
on cognition. In that survey, High blood pressure care with medication not only 
improves the cardiovascular health of older people, but can also reduce their risk 
of dementia and AD [27, 28]. The combined risk ratio of dementia preferred care 
in a meta-analysis of antihypertensive trials [29]. There is no strong evidence from 
Figure 3. 
Chronic kidney disease and alzheimer’s associated renin angiotensin aldosterone system share ageing related 
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the trials in a systematic analysis of hypertension research to confirm that decreas-
ing blood pressure prevents the development of dementia or cognitive decline 
in hypertensive patients with no clear previous CVD. [30]. However, the occur-
rence of fatal and non-fatal stroke has been greatly decreased in many studies of 
hypertension treatment, and it is very important since a history of stroke doubles 
the risk of dementia in both patients with non CKD and hemodialysis. In CKD 
patients, Anemia has also been identified as a risk factor for cognitive decline in 
CKD patients, and our studies have shown correction of anemia with recombinant 
erythropoietin therapy to improve cognitive measures, such as AD markers and 
neuropsychological tests [4, 5].
6. Future directions and challenges
This chapter explores the relationship between RAAS, cognitive dysfunction 
anemic CKD patients and EPO. We then hypothesized that the EPO may inhibit 
ACE2 interest and likely eventually alter complicated signaling cascades to boost 
cognition through changes in AD markers. A main aspect of this assessment is that 
in anemic CKD sufferers with cognitive impairment, the limited molecular effects 
of the treatment with EPO are crystal-clear. I may conclude by saying that a bright 
future for the EPO remedy. In order to better understand the mechanisms under-
lying the effects of EPO in anemic CKD with AD patients, further research into 
pharmacogenomics and clinical trials is required.
© 2021 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms 
of the Creative Commons Attribution License (http://creativecommons.org/licenses/
by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, 
provided the original work is properly cited. 
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